This company has been marked as potentially delisted and may not be actively trading. Alterity Therapeutics (PRAN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock PRAN vs. NLTX, ENTA, SGMT, MCRB, MGNX, VIRI, RENB, TLSA, COYA, and BHSTShould you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Neoleukin Therapeutics (NLTX), Enanta Pharmaceuticals (ENTA), Sagimet Biosciences (SGMT), Seres Therapeutics (MCRB), MacroGenics (MGNX), Virios Therapeutics (VIRI), Renovaro (RENB), Tiziana Life Sciences (TLSA), Coya Therapeutics (COYA), and BioHarvest Sciences (BHST). These companies are all part of the "medical" sector. Alterity Therapeutics vs. Neoleukin Therapeutics Enanta Pharmaceuticals Sagimet Biosciences Seres Therapeutics MacroGenics Virios Therapeutics Renovaro Tiziana Life Sciences Coya Therapeutics BioHarvest Sciences Neoleukin Therapeutics (NASDAQ:NLTX) and Alterity Therapeutics (NASDAQ:PRAN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk, community ranking and dividends. Which has higher earnings & valuation, NLTX or PRAN? Alterity Therapeutics has higher revenue and earnings than Neoleukin Therapeutics. Alterity Therapeutics is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeoleukin TherapeuticsN/AN/A-$57.56M-$3.11-3.10Alterity Therapeutics$150K183.93-$6.40M-$0.70-4.43 Do institutionals & insiders have more ownership in NLTX or PRAN? 52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 3.6% of Alterity Therapeutics shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer NLTX or PRAN? Alterity Therapeutics received 138 more outperform votes than Neoleukin Therapeutics when rated by MarketBeat users. Likewise, 57.67% of users gave Alterity Therapeutics an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote. CompanyUnderperformOutperformNeoleukin TherapeuticsOutperform Votes5045.87% Underperform Votes5954.13% Alterity TherapeuticsOutperform Votes18857.67% Underperform Votes13842.33% Is NLTX or PRAN more profitable? Alterity Therapeutics' return on equity of 0.00% beat Neoleukin Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neoleukin TherapeuticsN/A -37.22% -30.91% Alterity Therapeutics N/A N/A N/A Does the media prefer NLTX or PRAN? In the previous week, Alterity Therapeutics had 1 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 1 mentions for Alterity Therapeutics and 0 mentions for Neoleukin Therapeutics. Neoleukin Therapeutics' average media sentiment score of 0.00 equaled Alterity Therapeutics'average media sentiment score. Company Overall Sentiment Neoleukin Therapeutics Neutral Alterity Therapeutics Neutral Which has more volatility and risk, NLTX or PRAN? Neoleukin Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. SummaryAlterity Therapeutics beats Neoleukin Therapeutics on 9 of the 12 factors compared between the two stocks. Remove Ads Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRAN vs. The Competition Export to ExcelMetricAlterity TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.59M$6.77B$5.58B$7.92BDividend YieldN/A2.80%5.35%4.04%P/E Ratio-4.437.1123.0918.81Price / Sales183.93207.46368.8188.91Price / CashN/A65.6738.1634.64Price / Book2.216.146.694.18Net Income-$6.40M$142.11M$3.20B$247.10M Alterity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRANAlterity TherapeuticsN/A$3.10-2.5%N/A+63.1%$27.59M$150,000.00-4.4314NLTXNeoleukin TherapeuticsN/A$14.21-6.7%N/A-79.4%$133.55MN/A-4.5790High Trading VolumeENTAEnanta Pharmaceuticals3.5986 of 5 stars$6.20-1.7%$17.25+178.2%-67.6%$132.27M$66.59M-1.25160SGMTSagimet Biosciences2.8699 of 5 stars$4.13+3.5%$23.00+456.9%-51.9%$126.69M$2M-2.898Short Interest ↓MCRBSeres Therapeutics3.381 of 5 stars$0.71+0.3%$4.00+460.9%-11.1%$124.34M$126.33M-3.10330Positive NewsMGNXMacroGenics3.8288 of 5 stars$1.96-1.8%$7.63+289.0%-90.8%$123.02M$148.34M-1.24430VIRIVirios Therapeutics0.4248 of 5 stars$6.33-7.3%$3.00-52.6%+811.1%$121.90MN/A-23.445RENBRenovaro0.4777 of 5 stars$0.72+2.6%N/A-81.4%$114.04MN/A-0.7720Gap UpTLSATiziana Life Sciences0.6343 of 5 stars$1.08-2.7%N/A+145.6%$113.83MN/A0.008News CoverageCOYACoya Therapeutics2.2423 of 5 stars$6.65-0.4%$17.00+155.6%-34.2%$111.22M$3.55M-10.236BHSTBioHarvest SciencesN/A$6.71+8.1%$13.00+93.7%N/A$110.21M$22.43M-5.37N/AEarnings ReportGap Down Remove Ads Related Companies and Tools Related Companies Neoleukin Therapeutics Competitors Enanta Pharmaceuticals Competitors Sagimet Biosciences Competitors Seres Therapeutics Competitors MacroGenics Competitors Virios Therapeutics Competitors Renovaro Competitors Tiziana Life Sciences Competitors Coya Therapeutics Competitors BioHarvest Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRAN) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredWhy Elon Musk Is Investigating Fort KnoxWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
